Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Rheumatoid Arthritis Pharmaceutical Market in China 2021
15 March 2021
The rheumatoid arthritis pharmaceutical market in China in terms of revenue is set to grow by US$ 7 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 21.8% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for rheumatoid arthritis pharmaceutical. The China rheumatoid arthritis pharmaceutical market is segmented on the basis of type. By type, it is categorized into conventional synthetic disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory pharmaceuticals, and others.
The report has profiled some of the key players of the market such as AbbVie Inc., Johnson & Johnson International Inc., Pfizer Inc., Roche Holding AG, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the rheumatoid arthritis pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Type: conventional synthetic disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory pharmaceuticals, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China rheumatoid arthritis pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the rheumatoid arthritis pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Rheumatoid Arthritis Pharmaceutical Market by Type
4.1 Conventional Synthetic Disease-Modifying Antirheumatic Drugs (Dmards)
4.2 Non-Steroidal Anti-Inflammatory Pharmaceuticals
5. Company Profiles
5.1 AbbVie Inc.
5.2 Johnson & Johnson International, Inc.
5.3 Pfizer, Inc.
5.4 Roche Holding AG
5.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
5.6 Zhejiang Hisun Pharmaceutical Co., Ltd.
6.1 About StrategyHelix